Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase
© Petrella and Brinckerhoff; licensee BioMed Central Ltd. 2006
Received: 04 October 2006
Accepted: 01 December 2006
Published: 01 December 2006
Metastatic renal cell carcinoma (RCC) remains the leading cause of mortality in patients with clear cell RCC arising from mutations in the von Hippel Lindau (VHL) tumor suppressor. Successful RCC tumor suppression by VHL requires the negative regulation of hypoxia inducible factor alpha (HIF alpha) protein and its downstream targets. Thus, identification of HIF target genes responsible for RCC tumor progression will aid in the development of therapies for this disease. We previously identified membrane type-1 matrix metalloproteinase (MT1-MMP) as a transcriptional target of HIF-2alpha in RCC cells null for VHL and showed that MT1-MMP is overexpressed in these cells. MT1-MMP is a key regulator of tumor progression through its functions as a matrix-degrading enzyme, as well as its ability to cleave factors, such as adhesion molecules and other MMPs. The aim of this study was to investigate the contribution of MT1-MMP to the invasive potential of RCC cells using in vitro type I collagen degradation and invasion assays.
We evaluated RCC cells wild-type (WT8) and null (pRc-9) for VHL for invasive characteristics and showed that the pRc-9 cells demonstrated a greater propensity for both invasion and degradation of a type I collagen matrix. Furthermore, overexpression of either HIF-2alpha or MT1-MMP in the poorly invasive cell line, WT8, promoted collagen degradation and invasion of these cells. Finally, using RNAi, we show that inhibition of MT1-MMP suppresses tumor cell invasion of RCC cells.
Our results suggest that MT1-MMP is a major mediator of tumor cell invasiveness and type I collagen degradation by VHL RCC cells that express either MT1-MMP or HIF-2alpha. As such, MT1-MMP may represent a novel target for anti-invasion therapy for this disease.
Kidney cancer represents ~3% of cancer deaths worldwide and is the most deadly of the common urological diseases . While combined nephrectomy and immunotherapy are standard care for localized primary renal cell carcinoma (RCC) tumors, approximately 30% of these treated patients will eventually develop metastases . Additionally, one third of patients present with metastatic disease at time of diagnosis of the RCC primary tumor . Treatment of metastatic RCC remains difficult primarily due to the resistance of the tumors to adjuvant and immunotherapies . With the median survival of metastatic RCC patients being less than one year, investigation into more effective anti-metastatic therapies is clearly warranted [3, 5–7].
Renal cell carcinoma is classified into four histological subtypes, including clear cell, papillary, chromophobe, and collecting duct . Almost 80% of sporadic RCC is of the clear cell subtype and results from inactivation of the tumor suppressor, von Hippel Lindau (VHL) . Loss of VHL function also manifests itself as a dominantly inherited familial cancer syndrome, impacting several organ systems [8, 9]. Life expectancy is greatly reduced for ~40% of VHL patients who develop RCC, most commonly due to complications from metastatic disease [5, 6, 10, 11].
The most well-characterized function of VHL is in controlling the oxygen-sensing mechanism of the cell through its regulation of hypoxia inducible factor (HIF) alpha subunits (1α,-2α,-3α) [10, 12]. HIF is a heterodimeric transcription factor consisting of two subunits, HIF-α and HIF-β . While the β-subunit of HIF is constitutively expressed, the HIF-α protein is labile and detectable only under hypoxic conditions or when VHL is inactivated [8, 13–15]. Under normoxic conditions, VHL negatively regulates the levels HIF-α subunit through ubiquitin-targeted protein degradation [16, 17]. Thus, inactivation of VHL in RCC is associated with increased levels of HIF-α isoforms and a subsequent increase in hypoxia-inducible genes, such as those involved in angiogenesis (VEGF, PDGF), erythropoiesis (EPO), glycolysis (Glut1), cell growth and survival (Cyclin G2, TGF-α), and cell migration (CXCR4), suggesting that the genes upregulated by the VHL-HIF pathway are involved in the progression of renal cell carcinoma [8, 13, 15].
Although the majority of VHL mutations abrogate the regulation of HIF-α protein, a few mutations exist that retain the ability for VHL to regulate HIF-α, and these mutations are not associated with the formation of RCC [9, 18]. In fact, expression of such a VHL mutant, which retains the ability to negatively regulate HIF-2α, suppresses tumor formation of VHL null RCC cells in vivo . These results demonstrate that successful tumor suppression in renal cells depends on the proper regulation of HIF-2α rather than on the presence of VHL. Further evidence suggests that HIF-2α, rather than HIF-1α, is the VHL target responsible for tumorigenesis . Indeed, inhibition of HIF-2α is required for tumor suppression by VHL in RCC in vivo [20–22]. These findings illustrate the importance of understanding the various roles that HIF-2α targets play in renal cell tumorigenesis.
Previously, we identified membrane-type 1 matrix metalloproteinase (MT1-MMP) as a target gene of HIF-2α in RCC cells mutant for VHL . MT1-MMP is a membrane bound member of the family of zinc-dependent endopeptidases known as the matrix metalloproteinases (MMPs), which function in remodeling the extracellular matrix (ECM) [24, 25]. Due to their vast repertoire of substrates and functions in normal cellular processes, MMPs are strictly regulated to guarantee appropriate, homeostatic proteolytic events [26, 27]. Elevated levels of MMPs have been linked to the invasive behavior of most human cancers as well as to other characteristics of tumors [25, 26, 28]. In addition to pericellular proteolysis of type I collagen, MT1-MMP is known to control cell-ECM contacts, localize to the leading edge of invasive cells, cleave adhesion molecules, and activate latent MMP-2 and MMP-13 . As a result, MT1-MMP plays multiple roles in tumorigenesis, including tumor invasion, regulation of tumor cell growth, cell migration, and angiogenesis [29, 30]. Our previous data suggest that the loss of the VHL tumor suppressor, and subsequent stability of HIF-2α, leads to the induction of MT1-MMP expression in RCC. Interestingly, MT1-MMP expression has been linked to advanced stages of RCC [31, 32].
Given the important role of MT1-MMP in the progression of other cancers , we hypothesized that as a HIF-2α target, MT1-MMP may play a role in the progression of VHL-/- RCC tumor invasion to metastatic disease. A metastatic tumor cell must invade through two main extracellular matrix barriers: interstitial collagen in the stromal environment (comprised mainly of type I collagen) and basement membrane (comprised primarily of type IV collagen) . Koochekpour et al. showed in vitro that VHL-/- RCC cell invasion of type IV collagen is enhanced by the addition of neutralizing antibodies to TIMPs (tissue inhibitors of matrix metalloproteinases), the natural inhibitors of MMP activity, thereby implicating a role of MMPs in this invasion . These authors also showed that VHL mutant RCC cells overexpress the gelatinases, MMP-2 and MMP-9, which function to degrade type IV collagen found in basement membrane. In our previous studies, we reported that MT1-MMP is the main type I collagenolytic enzyme expressed by VHL null RCC cells, suggesting that this enzyme may mediate RCC invasion of type I collagen . Therefore, in this report, we specifically investigated the role of MT1-MMP in VHL RCC tumor cell invasion using in vitro assays to measure the ability of the cells to degrade type I collagen and to invade through a type I collagen matrix. Using gene overexpression studies and RNAi, our data directly link HIF-2α and MT1-MMP expression to an invasive phenotype of RCC cells, and targeted inhibition of MT1-MMP is required to block this invasion. We conclude that MT1-MMP is the primary mediator of both tumor cell invasion and degradation of type I collagen in these RCC cells and may represent an effective target for the treatment of invasive renal cell carcinoma.
VHL expression inhibits invasive properties of RCC cells
Renal cell carcinoma cell lines
Invasive tumor cells have the ability to migrate and to remodel the surrounding, restrictive ECM using enzymes, such as MT1-MMP, for pericellular proteolysis [36, 39]. To ask whether the observed increase in cell invasion by the pRc-9 cells involves increased matrix degradation, we measured the ability of these cells to degrade a type I collagen matrix using an in vitro collagen degradation assay. This assay is based upon the fact that when a fibrillar collagen gel is degraded by cells embedded in it, culture medium is liberated. This medium can be recovered and weighed, and the amount of medium liberated provides a simple, but accurate, measure of matrix destruction [40, 41]. Indeed, we found that collagen degradation was increased by approximately 25% (P < 0.005) in the VHL null cell line, pRc-9, as compared to the WT8 cells expressing wild-type VHL, indicating that the lack of VHL function promotes type I collagen degradation (Figure 1B). A similar increase in collagen degradation was observed in the VHL null 786-0 parental line (data not shown).
Expression of HIF-2α or MT1-MMP is sufficient to increase the invasive potential of RCC cells wild-type for VHL
To further test this hypothesis, we transiently transfected an MT1-MMP expression construct (MTpc3SE) into the WT8 cells and measured the ability of these transfectants to degrade type I collagen. This experimental design allowed us to study the effects of MT1-MMP expression on collagen invasion in the context of wild-type VHL and HIF-2α instability, thereby eliminating the contribution of other factors related to VHL mutations. Increased expression of MT1-MMP in the MTpc3SE transfected cells was confirmed by real-time RT-PCR, and MT1-MMP mRNA levels were approximately six-fold greater than the empty vector control transfectants (Figure 2B). The difference in MT1-MMP levels in these transfectants is comparable to the difference in endogenous MT1-MMP levels in the WT8 and pRc-9 cells previously published . Furthermore, overexpression of MT1-MMP increased collagen degradation of the WT8 cells by approximately 30% (P < 0.0001; Figure 2C), again resembling the increase in degradation measured in the pRc-9 cells as well as the HIF-2α transfected WT8 cells (see Figures 1B, 2A). These data indicate that MT1-MMP may be the HIF target gene responsible for the increased collagen degradation by the VHL mutant cells since, to our knowledge, no other HIF target with the ability to cleave type I collagen has been identified in these cells.
Next, we tested whether MT1-MMP expression was sufficient to promote collagen invasion of the WT8 cells by transient expression of the MTpc3SE construct in these cells and measured the ability of the transfectants to invade through a type I collagen matrix using the assay system as described in Figure 1. Expression of MT1-MMP in the WT8 cells increased collagen invasion approximately two-fold compared to empty vector transfected cells, showing that exogenous MT1-MMP expression alone drives the invasiveness of cells that retain VHL function (P < 0.005; Figure 2D). Importantly, the difference in invasiveness between the WT8 transfectants mimics the difference in collagen invasion observed between the WT8 and pRc-9 cells (see Figure 1A). Together with our previous finding that MT1-MMP expression is regulated by HIF-2α in VHL null cells , our data suggest that one mechanism by which VHL may inhibit tumor invasion is by suppressing MT1-MMP expression through the negative regulation of HIF-2α protein.
Inhibition of MT1-MMP is necessary to decrease invasive properties of RCC cells expressing MT1-MMP or HIF-2α
To extend these findings, we asked if MT1-MMP was necessary for VHL RCC cell invasion of collagen using RNAi to specifically inhibit MT1-MMP expression. We could not use the pRc-9 cell line for these experiments due to the sensitivity of these cells to transfection and subsequent manipulations. Although expression of MT1-MMP was effectively reduced by three different targeting siRNAs in the pRc-9 cells (data not shown), once transfected, the cells did not survive trypsinization and culturing on top of collagen for use in the invasion assays.
In addition to its function as a matrix-degrading enzyme, MT1-MMP also acts as a cell surface receptor for pro-MMP-2 and promotes MMP-2 activation [46–48]. Specifically, MT1-MMP, TIMP-2 and pro-MMP-2 exist in a trimolecular complex at the cell membrane . When MT1-MMP levels are in excess of TIMP-2 and pro-MMP-2, a free MT1-MMP molecule cleaves the propeptide sequence of pro-MMP-2 (72 kDa), thereby generating the intermediate (69 kDa) form . Fully active (67 kDa) MMP-2 is achieved by either intermolecular autolytic cleavage or by the activity of other enzymes [46, 47, 50]. WT8 cells express low levels of MMP-2 as well as TIMP-2 [23, 34]. To confirm that the reduction in MT1-MMP protein by siRNA was reflected in an inhibition of MT1-MMP enzyme activity, we measured the presence of pro, intermediate, and active forms of MMP-2 in the conditioned media collected from the transfectants using gelatin zymography. Expression of MTpc3SE in the WT8 cells resulted in the presence of the intermediate and active forms of MMP-2 (Figure 3B). Inhibition of MT1-MMP activity by each MT1-MMP siRNA was demonstrated by the absence of the MMP-2 intermediate and active species in these samples as compared to the media from the siRNA control transfectants (Figure 3B). The only other MMPs constitutively expressed by these cells in addition to MT1-MMP are MMP-2 and MMP-9 . Therefore, it is important to note that the MT1-MMP siRNAs have no effect on the expression levels of MMP-2 or MMP-9 as seen by the unchanged levels of the bands representing these proteins in Figure 3B, confirming the specificity of these siRNAs against MT1-MMP.
Next, the ability of the siRNA transfectants to invade through a type I collagen matrix was measured using a similar in vitro invasion assay system described in the previous Figures. For these invasion assays, we used type I collagen-coated FluoroBlok™ membrane transwell inserts. FluoroBlok™ membranes block the transmission of light; therefore, non-invasive cells are not detectable, whereas invasive, pCMV-eGFP transfected cells can be counted by fluorescence imaging. By only visualizing GFP-expressing cells that have invaded, we could specifically quantitate the number of transfected cells that had invaded collagen while discounting the non-transfected cells. As before (see Figure 2D), WT8 cells expressing exogenous MT1-MMP displayed increased collagen invasion (P < 0.005; Figure 3C). Co-transfection of the control siRNA oligo had no significant effect on this increased invasion by MT1-MMP, whereas each of the three specific MT1-MMP siRNA oligos inhibited collagen invasion of the MT1-MMP transfectants by greater than 85% (Figure 3C). Taken together, these data suggest that MT1-MMP is important for tumor cell invasion by RCC cells.
Renal cell carcinoma cells that have lost VHL tumor suppressor function lose the ability to negatively regulate HIF-2α protein levels, thereby allowing HIF-2α protein to accumulate and dimerize with HIF-β to form a functional transcription factor . Consequently, downstream targets of HIF, such as MT1-MMP, are constitutively transcribed, and activation of these targets causes RCC tumor formation in xenograph models [20–22]. Defining the HIF-2 targets responsible for VHL null RCC tumor progression is important to understand the mechanisms of renal tumor development. It is not yet known whether elevated expression of MT1-MMP contributes to RCC tumorigenesis or progression to metastatic disease.
When compared to several of the secreted MMPs, MT1-MMP and MT2-MMP are the only MMPs able to confer collagen invasive capabilities to non-invasive cells, thereby suggesting that pericellular proteolysis is critical for tumor cell migration and invasion . Furthermore, specific inhibition of MT1-MMP in tumor cells overexpressing MT1-MMP is sufficient to suppress tumor cell migration, invasion, proliferation, and metastasis [53–55]. Recently, the importance of MT1-MMP in cancer progression has been demonstrated by the finding that overexpression of MT1-MMP in non-malignant cells was sufficient to drive tumorigenicity . In keeping with these findings, we previously described a mechanism of MT1-MMP transcriptional upregulation in VHL mutant RCC cells and hypothesized that MT1-MMP may play a role in the invasion of renal cell carcinoma .
Here, we provide evidence supporting the importance of MT1-MMP in the invasive properties of RCC cells. First, our data show that RCC cells null for VHL (pRc-9) have a greater propensity for collagen degradation and invasion than RCC cells wild-type for VHL (WT8), suggesting that the pRc-9 cells have increased invasive potential (Figure 1). Further, overexpression of HIF-2α or MT1-MMP was sufficient to confer increased degradative and invasive abilities to the WT8 cells in type I collagen (Figure 2). Finally, inhibition of collagen invasion by WT8 cells transfected to express either MT1-MMP or HIF-2α required specific inhibition of MT1-MMP expression (Figures 3, 4). Importantly, collagen invasion of the HIF-2α transfectants was almost completely abrogated (>90%) by the MT1-MMP siRNAs, suggesting that MT1-MMP is the HIF-2α target primarily responsible for collagen invasion by these cells.
The process of matrix invasion by a tumor cell requires both degradation of ECM components as well as cell migration . In the pRc-9 cells, migration may result from the lack of VHL, which regulates migration through various mechanisms, including the regulation of actin filaments , integrin fibrillar adhesions , and endocytosis of FGFR1 . By performing siRNA experiments in a wild-type VHL background, we determined that invasion of the RCC cells was dependent on MT1-MMP rather than on the dysregulation of other VHL targets, suggesting that MT1-MMP may be responsible for RCC tumor invasion in the stromal compartment.
Our siRNA studies showed that inhibition of MT1-MMP expression prevented the activation of pro-MMP-2 as a measure of functional inhibition of MT1-MMP (Figure 3B) [46–48]. Thus, it is plausible that MT1-MMP may also contribute to RCC invasion of basement membrane through its regulation of pro-MMP-2 activation since MMP-2 degrades type IV collagen, the main component of basement membrane . Interestingly, expression MMP-2 has been correlated with advanced stages of RCC, and MMP-2 activity, along with histological grade, stage, and T classification, has been identified as a significant predictor of RCC clinical outcome [58–60].
Since the expression of the MT1-MMP siRNAs inhibited the activation of pro-MMP-2 by MT1-MMP (Figure 3B), our data does not exclude the possibility that MMP-2 activity may be required for type I collagen invasion by these RCC cells. However, this situation seems unlikely. Although MMP-2 has been shown to cleave fibrillar type I collagen, its ability to do so is less effective than known collagenases and requires a cell-free, TIMP-free system , which was not the condition under which we performed our experiments. In particular, the WT8 cells used in the siRNA studies (Figures 3, 4) express TIMP-1 and TIMP-2, as previously described ; thus, MMP-2 may not cleave fibrillar type I collagen under our experimental conditions. Further, the intermediate form of MMP-2, a species generated only when MT1-MMP and TIMP-2 are present at specific ratios, is predominant in these cells (Figure 3C) . Thus, it is unlikely that in our system, MMP-2 is playing a substantial role in the type I collagen invasion by these cells. Nonetheless, since MMP-2 activity is dependent on MT1-MMP [46–48], we conclude from our data that MT1-MMP is required for type I collagen invasion by these RCC cells. Thus, we posit that MT1-MMP may initiate local invasion by RCC tumors by promoting both cell migration and invasion through cleavage of adhesion molecules, such as CD44 and integrins, pro-MMP-2, and by pericellular proteolysis of type I collagen fibrils in the stromal environment [30, 61]. Supporting this hypothesis, MT1-MMP mRNA expression is increased in invasive RCC tumors when compared to tumors that remain localized .
Our experiments using HIF-2α expression in the WT8 cells demonstrate that HIF-2α increased type I collagen invasion despite the presence of wild-type VHL, and this increased invasion was dependent on MT1-MMP (Figure 4C). Kurban et al. recently showed that HIF-2α expression in a VHL wild-type background does not promote invasion of Matrigel , a reconstituted basement membrane mainly comprised of type IV collagen and laminin . The authors concluded from their studies that invasion by VHL mutant cells is mediated via a HIF-independent mechanism, namely, by the loss of ECM assembly. In their Matrigel invasion assays, Kurban et al. used the RCC cell line, WTPA, which stably expresses a HIF-2α variant that is not degraded by VHL in a VHL wild-type background . In their study, WTPA cells did not invade Matrigel as effectively as VHL mutant cells. Importantly, the authors showed that the more invasive cell lines expressed MMP-2, whereas WTPA cells did not. In our previous studies, we showed that pRc-9 and WTPA cells have stabilized HIF-2α protein and high levels of MT1-MMP when compared to WT8 cells . Like Kurban et al., we found that MMP-2 expression in WTPA cells was similar to WT8 cells and much lower than pRc-9 cells (data not shown), suggesting that the mechanism of MMP-2 overexpression in pRc-9 cells may not be HIF-2α dependent. Furthermore, invasion of Matrigel likely requires MMP-2 gelatinolytic activity through the degradation of type IV collagen, whereas type I collagen invasion, as in our assays, may not require MMP-2 activity. Taken together, we conclude that while RCC cell invasion of Matrigel may be HIF-independent, HIF-2α mediates type I collagen of RCC cells through the regulation of MT1-MMP.
Metastatic renal cell carcinoma remains difficult to treat. Although IL-2 and IFN-γ are the standard of care for these patients, the response rate is very low [4, 63]. The VHL-HIF pathway is a well-defined link to clear cell renal cell carcinogenesis, and thus targeting this pathway may benefit VHL RCC patients [64, 65]. Many next-generation agents currently in clinical trials for RCC are therapies targeting proteins regulated by the VHL-HIF pathway, such as VEGF and TGF-α [63, 64, 66]. We provide evidence supporting an important role for MT1-MMP in VHL RCC tumor cell invasion of type I collagen. We conclude that the loss of VHL tumor suppressor function is mechanistically linked to invasive behavior through the regulation of MT1-MMP, thereby implicating MT1-MMP as a potential therapeutic target for the treatment of invasive RCC.
Cell lines and cell culture
Cell lines were maintained in Dulbecco's Modified Eagle's Medium (Mediatech, Inc., Herndon, VA) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT), penicillin [100 U/mL], streptomycin [100 μg/mL], and L-glutamine and cultured at 37°C, 5%CO2. For serum-free conditions, DMEM supplemented with lactalbumin hydrosylate (2%), penicillin [100 U/mL], streptomycin [100 μg/mL], and L-glutamine was used. The WT8 and pRc-9 cell lines (kindly provided by William Kaelin, Dana-Farber Cancer Institute, Boston, MA) represent stable subclones of the 786-0 renal cell carcinoma cell line transfected with pRc/CMV-HA-VHL or pRc/CMV-empty, respectively . The 786-0 cell line (American Type Culture Collection (Manassas, VA) has a single VHL allele harboring a frameshift mutation at codon 104 resulting in a truncated, non-functional protein [16, 67]. The WT8 and pRc-9 cells were cultured under continuous selection with the addition of [1 mg/mL] G418 sulfate. Cells were washed with either Hank's Balanced Salt Solution (HBSS) (Mediatech, Inc.) or 1× PBS (13.7 mM NaCl, 0.27 mM KCl, 1.2 mM phosphate buffer, pH 7.4) (National Diagnostics, Atlanta, GA) as indicated in the different experimental procedures.
Reagents and plasmids
The pCMV-HIF-2α expression construct containing full-length cDNA of HIF-2α was a generous gift of Richard Bruick (University of Texas, Southwestern Medical Center, Dallas, TX) . The MT1-MMP expression construct, MTpc3SE, was a kind gift of Jouko Lohi (University of Helsinki, Helsinki, Finland), and contains full-length MT1-MMP cDNA downstream of a CMV promoter . The pCMV-eGFP expression construct is commercially available from BD Biosciences (San Jose, CA).
WT8 cells were plated in 6-well dishes at a density of 1.5 × 105 cells/well in DMEM+10% FBS in the absence of antibiotics or selection. At this density, the cells were ~90% confluent the following day and ready for transfection. Cells were then transiently transfected with 1 μg of DNA using Lipofectamine 2000™ Transfection Reagent (Invitrogen, Carlsbad, CA) following manufacturer's instructions for at least 12 hours before being washed three times with HBSS and switched to serum-free conditions for additional time depending on the experiment. Transfection with an empty vector (pRc/CMV) was used as a control for mock transfected cells . All transfections were performed in triplicate. Separate plates of cells were transfected with pCMV-eGFP to control for transfection efficiency under the given conditions. Transfection efficiency was determined as a percentage of GFP-expressing cells counted from 3 fields of 3 separate transfections, and the average transfection efficiency was approximately 50% in all experiments. Cells were harvested for either 1) functional assays as described under 'Collagen invasion assays' or 'Collagen degradation assay', 2) total RNA using the RNeasy kit as described under 'Real-time RT-PCR', or 3) protein expression analyses as described under 'ELISA' or 'Immunoblotting'.
Three siRNA duplex oligoribonucleotides targeting the MT1-MMP coding region (NM_604995) were designed using the Block-iT™ RNAi Designer program from the Invitrogen website. The Stealth™ RNAi Negative Control Duplex (cat# 12935-300; Invitrogen, Carlsbad, CA) is a proprietary non-targeting sequence with medium G/C content, which is similar to the G/C content of the target Stealth™ siRNAs. The target siRNA sequences are as follows: siRNA(1): 5'-AAUUUGCCAUCCUUCCUCUCGUAGG-3'; siRNA(2): 5'-AAGAGAGCAGCAUCAAUCUUGUCGG-3'; siRNA(3): 5'-AAUGAUGAUCACCUCCGUCUCCUCC-3'. WT8 cells were plated in 6-well dishes at a density of 1.5 × 105 cells/well as described under 'Transient transfections'. The following day, cells were transfected with 0.5 μg of pCMV-eGFP, 1 μg MTpc3SE or pCMV-HIF-2α, and 25 nM of either the control siRNA or one of the MT1-MMP target siRNAs using Lipofectamine 2000™ Transfection Reagent (Invitrogen) following manufacturer's instructions for co-transfection of plasmid DNA and siRNA oligos. Cells were transfected in the presence of serum for 24 hours before being washed three times with HBSS and switched to serum-free conditions for an additional 24 hours. Transfection efficiency was determined by GFP expression as described above before the cells were harvested for either protein expression or the collagen invasion assay as described under 'Fluoroblok™ invasion assay'. The average transfection efficiency was approximately 50% in all experiments. An empty vector control (pRc/CMV) was used to balance the amount of plasmid DNA in co-transfections . All transfections were performed in triplicate.
Total cellular RNA was purified using the RNeasy kit with on-column DNase I treatment (Qiagen, Valencia, CA). Reverse transcription and real-time PCR reactions were performed using the Taqman Reverse Transcription Reagent Kit and Syber Green Master Mix, respectively, following the manufacturer's protocol and as described previously (Applied Biosystems, Foster City, CA) . For each experiment, triplicate samples were obtained, and the cDNA for each was assayed in duplicate using a MJ Research DNA Engine Opticon thermal cycler. Data are presented as the average pg of MT1-MMP mRNA per ng of GFP mRNA and are representative of three or more experiments. Standard curves were included in each assay. Standards were prepared from serial log dilutions of plasmids carrying the appropriate cDNA as follows: MTpc3SE plasmid, 10 pg-0.001 pg; pCMV-eGFP plasmid, 1 ng-0.001 ng. Primer sequences are as previously published for MT1-MMP  and for eGFP .
The Matrix Metalloproteinase-14 (MMP-14) Biotrak Activity Assay System (GE Healthcare BioSciences Corp., Piscataway, NJ), a quantitative measure of MT1-MMP activity as a direct measure of MT1-MMP protein, was used to analyze MT1-MMP protein expression. The assay was conducted according to the manufacturer's protocol. A standard curve ranging from [0.125 ng/mL] to [8 ng/mL] was used to quantitate protein expression. Because the assay is colorimetric and does not require quenching, absorbance readings were taken at 6 hr, 9 hr, and 12 hrs after incubation with the substrate. The data presented represent the concentration of MT1-MMP in the samples at the timepoint at which the sample values fit the standard curve most appropriately. Total protein from the extracts was quantitated using the Bradford Assay (Bio-Rad, Hercules, CA) and used to normalize the MT1-MMP protein concentration in each sample.
Immunoblotting and antibodies
Whole cell lysates were harvested from transfection experiments by washing the cells twice with cold 1× PBS, adding 100 μL of SDS reducing buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 14.4 mM β-mercaptoethanol, 25% glycerol, 0.1% bromphenol blue), and boiling for 5 minutes. Proteins were resolved by SDS-PAGE and electrotransferred to Immobilon-P PVDF membranes (Millipore Corp., Bedford, MA). Membranes were blocked with 5% milk in Tris-buffered saline 0.1% Tween-20 at room temperature for 1–2 hours. Primary antibodies, HIF-2α polyclonal antibody, 1:1000 (Novus Biologicals, Littleton, CO) and actin monoclonal antibody, 1:5000 (Oncogene, Cambridge, MA), were diluted in blocking buffer and incubated with the membranes at room temperature for 2 hours. Appropriate secondary antibodies were diluted in blocking buffer and incubated with the membrane at room temperature for 1 hour. Proteins were visualized by Western Lightning Chemiluminescence Reagent (Perkin Elmer, Boston, MA).
Transfectants were cultured in serum-free media for 24 hours, and conditioned media was concentrated approximately 30 fold using BioMax 30 K NMWL membrane ultrafree filters (Millipore Corp., Bedford, MA) as per manufacturer's instructions. An equal volume of non-reducing buffer (60 mM Tris-HCl, pH 6.8, 25% glycerol, 0.1% bromphenol blue) was added to the concentrated media before being applied to a 10% SDS-PAGE gel impregnated with [2.8 mg/mL] gelatin. After electrophoresis, the gel was washed two times for 30 min in 50 mM Tris-HCl (pH 7.5), 5 mM CaCl2, 5 μM ZnCl2, plus 2.5% Triton X-100 followed by an overnight incubation at 37°C in the same buffer without Triton X-100. Gels were stained with Coomassie Brilliant Blue R-250 and then destained in 20% methanol, 10% glacial acetic acid. Activity was detected as transparent bands. Recombinant human pro-MMP-2 (R&D Systems, Minneapolis, MN) was used as a control for gelatinolytic activity at [1 ng/μL]. Active MMP-2 was obtained by incubation with 20 μM 4-Aminophenylmercuric acetate (APMA, Sigma, St. Louis, MO) at 37°C for 45 min.
Collagen invasion assays
Transwell® invasion assay
Cells were serum-starved overnight before being harvested for invasion assays. Transwell® inserts (Costar, 24 mm, Corning, NY) with 8.0 μm pore polycarbonate membranes were coated with 50 μL per cm2 growth area with type I collagen diluted to [1 mg/mL] in serum-free DMEM. Collagen was prepared from purified bovine type I collagen (Cohesion Technologies, Palo Alto, CA) following manufacturer's instructions. Briefly, collagen was neutralized to pH 7.4 with the addition of 10× PBS and 0.1 N NaOH. The collagen was allowed to gel on top of the membrane at 37°C for 1 hour. Next, either DMEM+10% FBS or serum-free DMEM was added to the lower chamber as a chemoattractant. Cells were plated on top of the collagen layer at a density of 3.0 × 105 cells per insert in serum-free media. Cells were allowed to invade for 4–6 hours. At time of harvest, media in the upper chamber was removed, and the upper surface of the membranes was scraped with a cotton swab to remove the collagen gel and remaining cells. The membranes were rinsed with 1× PBS and then removed from the inserts using a scalpel. The membranes were then stained with methylene blue and destained with water. Stained cells were viewed using an Olympus 1 × 50 inverted phase contrast microscope at 100× and counted from 3 fields. Pictures were taken with an Olympus Q Color 3 camera.
FluoroBlok™ invasion assay
siRNA transfected cells were serum-starved for 24 hours before being harvested for the invasion assay. HTS FluoroBlok™ inserts (BD Falcon Labware, 6.5 mm, Franklin Lakes, NJ) contain fluorescence blocking PET track-etched membranes with 8.0 μm pores. This invasion system allowed for real-time viewing of cell invasion without the need to end the experiment and process the membranes. The FluoroBlok™ membrane prevents the transmission of light to cells on top of the membrane; thus, only invaded, GFP-expressing cells invaded through the collagen-coated membrane can be viewed. FluoroBlok™ membranes were coated with 90 μL per cm2 growth area with type I collagen diluted to [0.8 mg/mL] in serum-free DMEM. Collagen was prepared from purified bovine type I collagen (Organogenesis, Inc., Canton, MA) and neutralized to pH 7.4 with a buffer containing 9.8% 10× EMEM, [200 nM] L-Glutamine, 2% lactalbumin hydrosylate, 7.5% sodium bicarbonate. The collagen was allowed to gel on top of the membrane at 37°C for 30 min. Next, DMEM+10% FBS was added to the lower chamber as a chemoattractant. Cells were plated on top of the collagen layer at a density of 2.1 × 104 cells per insert in serum-free DMEM. Invaded cells were viewed by GFP fluorescence using excitation from a 100 W Mercury lamp on an Olympus 1 × 50 inverted phase contrast microscope. Cells were counted from entire membranes at 40×.
Collagen degradation assay
Cells were serum-starved for at least 8 hours before being harvested for the assay. Cells were embedded as a mixture of fibrillar collagen and media in a 12-well assay format. Collagen was prepared from purified bovine type I collagen (Cohesion Technologies, Palo Alto, CA) following manufacturer's instructions. Briefly, collagen was neutralized to pH 7.4 with the addition of 10× PBS and 0.1 N NaOH. Next, 3.2 × 105 cells were mixed with 132 μL of neutralized collagen, and serum-free media was added to bring the total volume to 635 μL per well. The final concentration of collagen in the mixture was [0.5 mg/mL]. The collagen was allowed to gel for 1 hour at 37°C after which 635 μL of serum-free media was added to the top of the gel. Assays were harvested at 48 hours, and the overlying media was removed and weighed. The specific gravity of serum-free media was determined to be 1 mg/mL. Therefore, collagen degradation is reported as the volume of liberated media calculated by the difference of the weight of total media removed and weight of the original volume added (635 μg or 635 μL). This assay provides an accurate measure of collagen degradation in vitro [40, 41].
Statistical significance was calculated using the student's t-test available online  and are represented as +/- standard deviation (S.D.) of the mean. Significance was assigned to P values < 0.05.
We are grateful to the following for their generous gifts: Dr. William G. Kaelin, Jr. for use of the WT8 and pRc-9 cells, Dr. Richard Bruick for the pCMV-HIF-2α expression construct, and Dr. Jouko Lohi for the MTpc3SE expression construct. We also thank Dr. Peter S. Burrage, Sarah M. Eck, and Jessica Blackburn for critical reading of the manuscript. This work was supported by AR26599 and CA-77267 (C.E.B.) and by T32-AR-007576 (B.L.P.).
- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin. 2004, 54: 8-29.View ArticlePubMedGoogle Scholar
- Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS: Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005, 173: 1853-1862. 10.1097/01.ju.0000165693.68449.c3View ArticlePubMedGoogle Scholar
- Motzer RJ, Russo P, Nanus DM, Berg WJ: Renal cell carcinoma. Curr Probl Cancer. 1997, 21: 185-232. 10.1016/S0147-0272(97)80007-4View ArticlePubMedGoogle Scholar
- Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med. 1996, 335: 865-875. 10.1056/NEJM199609193351207View ArticlePubMedGoogle Scholar
- Hes FJ, van der Luijt RB, Lips CJ: Clinical management of Von Hippel-Lindau (VHL) disease. Neth J Med. 2001, 59: 225-234. 10.1016/S0300-2977(01)00165-6View ArticlePubMedGoogle Scholar
- Linehan WM, Walther MM, Zbar B: The genetic basis of cancer of the kidney. J Urol. 2003, 170: 2163-2172. 10.1097/01.ju.0000096060.92397.edView ArticlePubMedGoogle Scholar
- Goldman: Cecil Textbook of Medicine. 2004, , W.B. Saunders Company, 22nd.Google Scholar
- Barry RE, Krek W: The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Trends Mol Med. 2004, 10: 466-472. 10.1016/j.molmed.2004.07.008View ArticlePubMedGoogle Scholar
- Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol. 2004, 22: 4991-5004. 10.1200/JCO.2004.05.061View ArticlePubMedGoogle Scholar
- Sufan RI, Jewett MA, Ohh M: The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol. 2004, 287: F1-6. 10.1152/ajprenal.00424.2003View ArticlePubMedGoogle Scholar
- Singh AD, Shields CL, Shields JA: von Hippel-Lindau disease. Surv Ophthalmol. 2001, 46: 117-142. 10.1016/S0039-6257(01)00245-4View ArticlePubMedGoogle Scholar
- Kaelin WG: The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004, 10: 6290S-5S. 10.1158/1078-0432.CCR-sup-040025View ArticlePubMedGoogle Scholar
- Maynard MA, Ohh M: Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol. 2004, 24: 1-13. 10.1159/000075346View ArticlePubMedGoogle Scholar
- Safran M, Kaelin WG: HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest. 2003, 111: 779-783. 10.1172/JCI200318181PubMed CentralView ArticlePubMedGoogle Scholar
- Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003, 3: 721-732. 10.1038/nrc1187View ArticlePubMedGoogle Scholar
- Iliopoulos O, Kibel A, Gray S, Kaelin WG: Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995, 1: 822-826. 10.1038/nm0895-822View ArticlePubMedGoogle Scholar
- Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999, 399: 271-275. 10.1038/20459View ArticlePubMedGoogle Scholar
- Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG: von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001, 10: 1019-1027. 10.1093/hmg/10.10.1019View ArticlePubMedGoogle Scholar
- Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD: The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 2002, 1: 247-255. 10.1016/S1535-6108(02)00044-2View ArticlePubMedGoogle Scholar
- Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002, 1: 237-246. 10.1016/S1535-6108(02)00043-0View ArticlePubMedGoogle Scholar
- Kondo K, Kim WY, Lechpammer M, Kaelin WG: Inhibition of HIF2alpha Is Sufficient to Suppress pVHL-Defective Tumor Growth. PLoS Biol. 2003, 1: E83- 10.1371/journal.pbio.0000083PubMed CentralView ArticlePubMedGoogle Scholar
- Zimmer M, Doucette D, Siddiqui N, Iliopoulos O: Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res. 2004, 2: 89-95.PubMedGoogle Scholar
- Petrella BL, Lohi J, Brinckerhoff CE: Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene. 2005, 24: 1043-1052. 10.1038/sj.onc.1208305PubMed CentralView ArticlePubMedGoogle Scholar
- Seiki M: Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 2003, 194: 1-11. 10.1016/S0304-3835(02)00699-7View ArticlePubMedGoogle Scholar
- Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001, 17: 463-516. 10.1146/annurev.cellbio.17.1.463PubMed CentralView ArticlePubMedGoogle Scholar
- Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2: 161-174. 10.1038/nrc745View ArticlePubMedGoogle Scholar
- Overall CM, Lopez-Otin C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002, 2: 657-672. 10.1038/nrc884View ArticlePubMedGoogle Scholar
- McCawley LJ, Matrisian LM: Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol. 2001, 13: 534-540. 10.1016/S0955-0674(00)00248-9View ArticlePubMedGoogle Scholar
- Seiki M, Yana I: Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci. 2003, 94: 569-574. 10.1111/j.1349-7006.2003.tb01484.xView ArticlePubMedGoogle Scholar
- Sounni NE, Noel A: Membrane type-matrix metalloproteinases and tumor progression. Biochimie. 2005, 87: 329-342. 10.1016/j.biochi.2004.07.012View ArticlePubMedGoogle Scholar
- Kitagawa Y, Kunimi K, Uchibayashi T, Sato H, Namiki M: Expression of messenger RNAs for membrane-type 1, 2, and 3 matrix metalloproteinases in human renal cell carcinomas. J Urol. 1999, 162: 905-909. 10.1097/00005392-199909010-00088View ArticlePubMedGoogle Scholar
- Skubitz KM, Skubitz AP: Differential gene expression in renal-cell cancer. J Lab Clin Med. 2002, 140: 52-64. 10.1067/mlc.2002.125213View ArticlePubMedGoogle Scholar
- Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992, 10: 145-155. 10.1007/BF00132746View ArticlePubMedGoogle Scholar
- Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF: The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol. 1999, 19: 5902-5912.PubMed CentralPubMedGoogle Scholar
- Sato H, Takino T, Miyamori H: Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci. 2005, 96: 212-217. 10.1111/j.1349-7006.2005.00039.xView ArticlePubMedGoogle Scholar
- Seiki M, Koshikawa N, Yana I: Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Metastasis Rev. 2003, 22: 129-143. 10.1023/A:1023087113214View ArticlePubMedGoogle Scholar
- Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D: Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J Biol Chem. 2000, 275: 20700-20706. 10.1074/jbc.M909970199View ArticlePubMedGoogle Scholar
- Kurban G, Hudon V, Duplan E, Ohh M, Pause A: Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res. 2006, 66: 1313-1319. 10.1158/0008-5472.CAN-05-2560View ArticlePubMedGoogle Scholar
- Friedl P, Wolf K: Proteolytic and non-proteolytic migration of tumour cells and leucocytes. Biochem Soc Symp. 2003, 277-285.Google Scholar
- Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CL, Brinckerhoff CE: Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem. 2004, 279: 33168-33176. 10.1074/jbc.M405102200View ArticlePubMedGoogle Scholar
- Wyatt CA, Geoghegan JC, Brinckerhoff CE: Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res. 2005, 65: 11101-11108. 10.1158/0008-5472.CAN-05-2446View ArticlePubMedGoogle Scholar
- Kamada M, Suzuki K, Kato Y, Okuda H, Shuin T: von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res. 2001, 61: 4184-4189.PubMedGoogle Scholar
- Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG, Iliopoulos O: The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998, 1: 959-968. 10.1016/S1097-2765(00)80096-9View ArticlePubMedGoogle Scholar
- Bluyssen HA, Lolkema MP, van Beest M, Boone M, Snijckers CM, Los M, Gebbink MF, Braam B, Holstege FC, Giles RH, Voest EE: Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Lett. 2004, 556: 137-142. 10.1016/S0014-5793(03)01392-9View ArticlePubMedGoogle Scholar
- Hsu T, Adereth Y, Kose N, Dammai V: Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem. 2006, 281: 12069-12080. 10.1074/jbc.M511621200PubMed CentralView ArticlePubMedGoogle Scholar
- Atkinson SJ, Crabbe T, Cowell S, Ward RV, Butler MJ, Sato H, Seiki M, Reynolds JJ, Murphy G: Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem. 1995, 270: 30479-30485. 10.1074/jbc.270.30.17797View ArticlePubMedGoogle Scholar
- Sato H, Takino T, Kinoshita T, Imai K, Okada Y, Stetler Stevenson WG, Seiki M: Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett. 1996, 385: 238-240. 10.1016/0014-5793(96)00389-4View ArticlePubMedGoogle Scholar
- Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995, 270: 5331-5338. 10.1074/jbc.270.10.5331View ArticlePubMedGoogle Scholar
- Kinoshita T, Sato H, Takino T, Itoh M, Akizawa T, Seiki M: Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. Cancer Res. 1996, 56: 2535-2538.PubMedGoogle Scholar
- Polette M, Birembaut P: Membrane-type metalloproteinases in tumor invasion. Int J Biochem Cell Biol. 1998, 30: 1195-1202. 10.1016/S1357-2725(98)00083-1View ArticlePubMedGoogle Scholar
- Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003, 425: 307-311. 10.1038/nature01874View ArticlePubMedGoogle Scholar
- Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ: Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol. 2000, 149: 1309-1323. 10.1083/jcb.149.6.1309PubMed CentralView ArticlePubMedGoogle Scholar
- Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M: Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene. 2003, 22: 8716-8722. 10.1038/sj.onc.1206962View ArticlePubMedGoogle Scholar
- Munoz-Najar UM, Neurath KM, Vumbaca F, Claffey KP: Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene. 2005.Google Scholar
- Nonaka T, Nishibashi K, Itoh Y, Yana I, Seiki M: Competitive disruption of the tumor-promoting function of membrane type 1 matrix metalloproteinase/matrix metalloproteinase-14 in vivo. Mol Cancer Ther. 2005, 4: 1157-1166. 10.1158/1535-7163.MCT-05-0127View ArticlePubMedGoogle Scholar
- Soulie P, Carrozzino F, Pepper MS, Strongin AY, Poupon MF, Montesano R: Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene. 2005, 24: 1689-1697. 10.1038/sj.onc.1208360View ArticlePubMedGoogle Scholar
- Esteban-Barragan MA, Avila P, Alvarez-Tejado M, Gutierrez MD, Garcia-Pardo A, Sanchez-Madrid F, Landazuri MO: Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res. 2002, 62: 2929-2936.PubMedGoogle Scholar
- Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, Dinney CP: Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol. 2001, 158: 735-743.PubMed CentralView ArticlePubMedGoogle Scholar
- Takahashi M, Oka N, Naroda T, Nishitani MA, Kanda K, Kanayama HO, Kagawa S: Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int J Urol. 2002, 9: 531-538. 10.1046/j.1442-2042.2002.00516.xView ArticlePubMedGoogle Scholar
- Walther MM, Kleiner DE, Lubensky IA, Pozzatti R, Nyguen T, Gnarra JR, Hurley K, Venzon D, Linehan WM, Stetler-Stevenson WG: Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology. 1997, 50: 295-301. 10.1016/S0090-4295(97)00220-3View ArticlePubMedGoogle Scholar
- Seiki M, Mori H, Kajita M, Uekita T, Itoh Y: Membrane-type 1 matrix metalloproteinase and cell migration. Biochem Soc Symp. 2003, 253-262.Google Scholar
- Bae SN, Arand G, Azzam H, Pavasant P, Torri J, Frandsen TL, Thompson EW: Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays. Breast Cancer Res Treat. 1993, 24: 241-255. 10.1007/BF01833264View ArticlePubMedGoogle Scholar
- Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M: Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets. 2005, 6: 835-846. 10.2174/138945005774574498View ArticlePubMedGoogle Scholar
- Maynard MA, Ohh M: Molecular targets from VHL studies into the oxygen-sensing pathway. Curr Cancer Drug Targets. 2005, 5: 345-356. 10.2174/1568009054629672View ArticlePubMedGoogle Scholar
- Kaelin WG: The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun. 2005, 338: 627-638. 10.1016/j.bbrc.2005.08.165View ArticlePubMedGoogle Scholar
- Shaheen PE, Bukowski RM: Emerging drugs for renal cell carcinoma. Expert Opin Emerg Drugs. 2005, 10: 773-795. 10.1517/14728126.96.36.1993View ArticlePubMedGoogle Scholar
- Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994, 7: 85-90. 10.1038/ng0594-85View ArticlePubMedGoogle Scholar
- Tian H, McKnight SL, Russell DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 1997, 11: 72-82.View ArticlePubMedGoogle Scholar
- Lohi J, Lehti K, Westermarck J, Kahari VM, Keski-Oja J: Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem. 1996, 239: 239-247. 10.1111/j.1432-1033.1996.0239u.xView ArticlePubMedGoogle Scholar
- Student's t-test analysis. [http://www.physics.csbsju.edu/stats/t-test.html]
- Aimes RT, Quigley JP: Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem. 1995, 270 (11): 5872-5876. 10.1074/jbc.270.11.5872View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.